Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00781443 |
This is a multicenter, randomized, double-blind, placebo-controlled study designed to demonstrate the safety and efficacy of MILR1444A compared with placebo in reducing the airway reaction to an inhaled aeroallergen solution in adult patients with mild allergic asthma. The study will randomize approximately 24 patients at five study centers. In the event of patient discontinuation from the study, additional patients may be enrolled at the discretion of the Sponsor.
Condition | Intervention | Phase |
---|---|---|
Allergic Asthma |
Drug: MILR1444A Drug: placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver), Placebo Control, Parallel Assignment |
Official Title: | A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma |
Estimated Enrollment: | 24 |
Study Start Date: | December 2008 |
Estimated Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental |
Drug: MILR1444A
Repeating subcutaneous injection
|
B: Placebo Comparator |
Drug: placebo
Repeating subcutaneous injection
|
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Todd Clobes | clobes.todd@gene.com |
United States, California | |
Allergy Research Foundation | Recruiting |
Los Angeles, California, United States, 90025 | |
Contact: Tamara Johnson 310-477-1734 ext 232 johnsontam@sbcglobal.net | |
West Coast Clinical Trials | Recruiting |
Long Beach, California, United States, 90806 | |
Contact: Maria Chona Kemp 562-997-8850 mariak@wcctrials2-4.com | |
United States, Missouri | |
Clinical Research Center LLC | Recruiting |
Saint Louis, Missouri, United States, 63141 | |
Contact: Kelly Esposito 314-514-8509 k.esposito@clinicalresearchcenter.com | |
Washington Univ School of Med | Recruiting |
St. Louis, Missouri, United States, 63110 | |
Contact: Tammy Koch 314-747-3063 tkoch@im.wustl.edu | |
United States, North Carolina | |
Duke Univ Medical Center | Recruiting |
Durham, North Carolina, United States, 27710 | |
Contact: Jeanne Woodard 919-668-0288 jeanne.woodard@duke.edu | |
United States, Wisconsin | |
Univ of Wisconsin-Madison | Recruiting |
Madison, Wisconsin, United States, 53762 | |
Contact: Jurga Zdanaviciene 608-263-6185 jxz@medicine.wisc.edu |
Study Director: | Edward Conner, M.D. | Genentech |
Responsible Party: | Genentech, Inc. ( Clinical Trials Posting Group ) |
Study ID Numbers: | ILR4544g |
Study First Received: | October 27, 2008 |
Last Updated: | March 3, 2009 |
ClinicalTrials.gov Identifier: | NCT00781443 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Asthma |
Hypersensitivity Lung Diseases, Obstructive Respiratory Insufficiency Bronchial Diseases Respiratory Tract Diseases Lung Diseases |
Respiration Disorders Hypersensitivity, Immediate Asthma Airway Obstruction Respiratory Hypersensitivity |
Hypersensitivity Lung Diseases, Obstructive Respiratory Insufficiency Immune System Diseases Bronchial Diseases Respiratory Tract Diseases |
Lung Diseases Respiration Disorders Hypersensitivity, Immediate Asthma Airway Obstruction Respiratory Hypersensitivity |